[HTML][HTML] Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

TA Chan, M Yarchoan, E Jaffee, C Swanton… - Annals of …, 2019 - Elsevier
Background Treatment with immune checkpoint blockade (ICB) with agents such as anti-
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or …

Reporting and interpreting decision curve analysis: a guide for investigators

B Van Calster, L Wynants, JFM Verbeek, JY Verbakel… - European urology, 2018 - Elsevier
Context Urologists regularly develop clinical risk prediction models to support clinical
decisions. In contrast to traditional performance measures, decision curve analysis (DCA) …

Urine TMPRSS2: ERG plus PCA3 for individualized prostate cancer risk assessment

SA Tomlins, JR Day, RJ Lonigro, DH Hovelson… - European urology, 2016 - Elsevier
Abstract Background TMPRSS2: ERG (T2: ERG) and prostate cancer antigen 3 (PCA3) are
the most advanced urine-based prostate cancer (PCa) early detection biomarkers. Objective …

Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer

E Castro, C Goh, D Leongamornlert, E Saunders… - European urology, 2015 - Elsevier
Background Germline BRCA mutations are associated with worse prostate cancer (PCa)
outcomes; however, the most appropriate management for mutation carriers has not yet …

Automated prostate cancer grading and diagnosis system using deep learning-based Yolo object detection algorithm

ME Salman, GÇ Çakar, J Azimjonov, M Kösem… - Expert Systems with …, 2022 - Elsevier
Purpose: Developing an artificial intelligence-based prostate cancer detection and
diagnosis system that can automatically determine important regions and accurately classify …

[HTML][HTML] Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis

KS Louie, A Seigneurin, P Cathcart, P Sasieni - Annals of Oncology, 2015 - Elsevier
Despite the extensive development of prostate cancer (PCa) risk models that are used for
patient–clinician decision-making for PCa screening, their predictive accuracy is unknown …

Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing

E Heitzer, P Ulz, J Belic, S Gutschi, F Quehenberger… - Genome medicine, 2013 - Springer
Background Patients with prostate cancer may present with metastatic or recurrent disease
despite initial curative treatment. The propensity of metastatic prostate cancer to spread to …

[HTML][HTML] Machine learning applications in radiation oncology

M Field, N Hardcastle, M Jameson, N Aherne… - Physics and Imaging in …, 2021 - Elsevier
Abstract Machine learning technology has a growing impact on radiation oncology with an
increasing presence in research and industry. The prevalence of diverse data including 3D …

[HTML][HTML] Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy

RB Den, K Yousefi, EJ Trabulsi, F Abdollah… - Journal of Clinical …, 2015 - ncbi.nlm.nih.gov
Purpose The optimal timing of postoperative radiotherapy (RT) after radical prostatectomy
(RP) is unclear. We hypothesized that a genomic classifier (GC) would provide prognostic …

[HTML][HTML] Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices

N Kinsella, J Helleman, S Bruinsma… - Translational …, 2018 - ncbi.nlm.nih.gov
In the last decade, active surveillance (AS) has emerged as an acceptable choice for low-
risk prostate cancer (PC), however there is discordance amongst large AS cohort studies …